[go: up one dir, main page]

CY1117374T1 - Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων - Google Patents

Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων

Info

Publication number
CY1117374T1
CY1117374T1 CY20151101146T CY151101146T CY1117374T1 CY 1117374 T1 CY1117374 T1 CY 1117374T1 CY 20151101146 T CY20151101146 T CY 20151101146T CY 151101146 T CY151101146 T CY 151101146T CY 1117374 T1 CY1117374 T1 CY 1117374T1
Authority
CY
Cyprus
Prior art keywords
therapeutic use
imidazopyridine
procedure
products
preparation
Prior art date
Application number
CY20151101146T
Other languages
English (en)
Inventor
Chantal Alcouffe
Reinhard Kirsch
Corentin Herbert
Gilbert Lassale
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117374(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of CY1117374T1 publication Critical patent/CY1117374T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

H εφεύρεση σχετίζεται με ενώσεις που αντιστοιχούν στον τύπο (I): R4 ΝΝ R1 Ο R2 R3 (I) 5 6 7 8 στον οποίο - R2 και R3 μαζί σχηματίζουν, με τα άτομα άνθρακα του πυρήνα φαινυλίου στον οποίο προσαρτώνται, έναν 6-μελή αζωτούχο ετεροκυκλικό δακτύλιο που αντιστοιχεί σε έναν από τους τύπους (Α), (Β) ή (C) παρακάτω: Ν Ν Ο Ο Ra Ra' Ν Ν Ο Rb Rb' Ν Ο Rc Rc" Rc' (A) (Β) (C) όπου οι κυματιστές γραμμές αναπαριστούν τον πυρήνα φαινυλίου στον οποίο τα R2 και R3 προσαρτώνται. Διαδικασία παρασκευής και θεραπευτική χρήση.
CY20151101146T 2010-07-06 2015-12-15 Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων CY1117374T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1055475A FR2962437B1 (fr) 2010-07-06 2010-07-06 Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
EP11743633.7A EP2590976B1 (en) 2010-07-06 2011-07-04 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof

Publications (1)

Publication Number Publication Date
CY1117374T1 true CY1117374T1 (el) 2017-04-26

Family

ID=43383651

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151101146T CY1117374T1 (el) 2010-07-06 2015-12-15 Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων

Country Status (37)

Country Link
US (2) US8759344B2 (el)
EP (1) EP2590976B1 (el)
JP (1) JP5889295B2 (el)
KR (1) KR101820548B1 (el)
CN (1) CN103080111B (el)
AR (1) AR082112A1 (el)
AU (1) AU2011275427B2 (el)
BR (1) BR112013000273B1 (el)
CA (1) CA2804915C (el)
CL (1) CL2013000016A1 (el)
CO (1) CO6650360A2 (el)
CR (1) CR20120643A (el)
CY (1) CY1117374T1 (el)
DK (1) DK2590976T3 (el)
EA (1) EA022690B1 (el)
EC (1) ECSP13012363A (el)
ES (1) ES2556754T3 (el)
FR (1) FR2962437B1 (el)
GT (1) GT201200346A (el)
HR (1) HRP20151309T1 (el)
HU (1) HUE025639T2 (el)
IL (1) IL223832A (el)
MA (1) MA34450B1 (el)
MX (1) MX2012015120A (el)
NI (1) NI201200192A (el)
NZ (1) NZ604973A (el)
PE (1) PE20130651A1 (el)
PH (1) PH12013500041A1 (el)
PL (1) PL2590976T3 (el)
PT (1) PT2590976E (el)
SG (1) SG186396A1 (el)
SI (1) SI2590976T1 (el)
TN (1) TN2012000608A1 (el)
TW (1) TWI520961B (el)
UY (1) UY33488A (el)
WO (1) WO2012004732A1 (el)
ZA (1) ZA201209632B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
LT3176170T (lt) 2012-06-13 2019-04-25 Incyte Holdings Corporation Pakeisti tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
MX393494B (es) 2013-04-19 2025-03-24 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
CN105531274A (zh) * 2013-09-11 2016-04-27 豪夫迈·罗氏有限公司 作为RORc调节剂的酮-咪唑并吡啶衍生物
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA51229A (fr) 2015-02-20 2021-03-24 Incyte Corp Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9640143B1 (en) * 2016-01-22 2017-05-02 Sony Corporation Active video projection screen coordinating grayscale values of screen with color pixels projected onto screen
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN111712245A (zh) 2018-03-28 2020-09-25 卫材R&D管理有限公司 用于肝细胞癌的治疗剂
TWI870349B (zh) 2018-05-04 2025-01-21 美商英塞特公司 Fgfr抑制劑之固體形式及其製備方法
EA202092649A1 (ru) 2018-05-04 2021-06-21 Инсайт Корпорейшн Соли ингибитора fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115835908A (zh) 2019-10-14 2023-03-21 因赛特公司 作为fgfr抑制剂的双环杂环
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114380752A (zh) * 2020-10-22 2022-04-22 南开大学 一种制备n-取代-2，4-喹唑啉二酮类化合物的合成方法
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN114016060B (zh) * 2021-11-23 2023-05-02 南昌大学 一种酚类化合物的合成方法
CN115978796B (zh) * 2022-12-26 2025-03-07 烟台宁远药业有限公司 取代含氮喹唑啉酮类化合物的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102808D0 (sv) 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
FR2838123B1 (fr) 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2859997B1 (fr) 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
CN100475815C (zh) 2003-09-25 2009-04-08 詹森药业有限公司 抑制hiv复制的嘌呤衍生物
FR2865934B1 (fr) 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
WO2006057946A2 (en) * 2004-11-22 2006-06-01 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer agents and prodrugs thereof
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
CN1733742A (zh) * 2005-07-12 2006-02-15 浙江大学 苯并三嗪衍生物的制备及用途
FR2893616B1 (fr) 2005-11-23 2008-01-04 Sanofi Aventis Sa Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant
FR2896247B1 (fr) 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
CN1887878A (zh) * 2006-07-26 2007-01-03 浙江大学 三嗪氮氧化物及合成方法和用途
EP2120938A4 (en) 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
CN101239978A (zh) 2008-03-05 2008-08-13 南方医科大学 一种咪唑并吡啶类化合物
CA2779951A1 (en) 2009-11-06 2011-05-12 Piramal Life Sciences Limited Imidazopyridine derivatives
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
NZ604973A (en) 2014-05-30
MA34450B1 (fr) 2013-08-01
BR112013000273B1 (pt) 2020-09-29
WO2012004732A1 (en) 2012-01-12
CA2804915C (en) 2018-07-03
HRP20151309T1 (hr) 2016-01-01
SG186396A1 (en) 2013-01-30
CA2804915A1 (en) 2012-01-12
TWI520961B (zh) 2016-02-11
TW201217370A (en) 2012-05-01
US9452164B2 (en) 2016-09-27
CO6650360A2 (es) 2013-04-15
US20140243328A1 (en) 2014-08-28
CL2013000016A1 (es) 2013-04-19
US8759344B2 (en) 2014-06-24
MX2012015120A (es) 2013-05-01
EA201291414A1 (ru) 2013-05-30
ECSP13012363A (es) 2013-01-31
NI201200192A (es) 2013-05-13
JP5889295B2 (ja) 2016-03-22
EP2590976B1 (en) 2015-09-16
KR20130128363A (ko) 2013-11-26
BR112013000273A2 (pt) 2017-10-31
FR2962437B1 (fr) 2012-08-17
ES2556754T3 (es) 2016-01-20
AR082112A1 (es) 2012-11-14
GT201200346A (es) 2014-05-20
JP2013530211A (ja) 2013-07-25
EP2590976A1 (en) 2013-05-15
HUE025639T2 (en) 2016-04-28
TN2012000608A1 (en) 2014-04-01
CR20120643A (es) 2013-02-05
PT2590976E (pt) 2016-01-20
PE20130651A1 (es) 2013-06-20
UY33488A (es) 2012-01-31
CN103080111A (zh) 2013-05-01
AU2011275427B2 (en) 2016-04-21
IL223832A (en) 2017-03-30
KR101820548B1 (ko) 2018-01-19
EA022690B1 (ru) 2016-02-29
FR2962437A1 (fr) 2012-01-13
PL2590976T3 (pl) 2016-03-31
ZA201209632B (en) 2014-03-26
AU2011275427A1 (en) 2013-01-24
PH12013500041A1 (en) 2017-08-23
SI2590976T1 (sl) 2016-01-29
US20130116250A1 (en) 2013-05-09
DK2590976T3 (en) 2015-12-21
BR112013000273A8 (pt) 2018-04-24
CN103080111B (zh) 2016-06-15

Similar Documents

Publication Publication Date Title
CY1117374T1 (el) Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων
CY1116945T1 (el) Παραγωγα ινδολιζινης, διεργασια για την παρασκευη αυτης και θεραπευτικη χρηση αυτης
CY1125279T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1122933T1 (el) Ενωσεις θειαζολοκαρβοξαμιδιων και πυριδινοκαρβοξαμιδιου χρησιμες ως αναστολεις κινασης ριμ
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
CO7141456A2 (es) Derivados de aril-sultamo como moduladores de rorc
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
UY35377A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
CY1123811T1 (el) Κρυσταλλικη μορφη αναστολεα pde4
CY1118739T1 (el) Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
BR112012029647A2 (pt) novos derivados de pirimidinas
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
JO3073B1 (ar) مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3
CY1116120T1 (el) Παραγωγα ιμιδαζοπυριδινης ή ιμιδαζοπυριμιδινης ως αναστολεις φωσφοδιεστερασης 10α
CY1119289T1 (el) Παραγωγα 1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης υποκατεστημενα με ετεροκυκλικους δακτυλιους ως αντι-ιικοι παραγοντες αναπνευστικου συγκυτιακου ιου
CY1119425T1 (el) Ενωσεις φαινοξυαιθυλο πιπεριδινης
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
CY1115863T1 (el) Ενωσεις τριαζολοπyριδινης
CY1119442T1 (el) Παραγωγα 2,3-διϋδρο-1η-ιμιδαζο {1,2-α} πυριμιδιν-5-ονης, παρασκευη αυτων και φαρμακευτικη χρηση αυτων
CY1119114T1 (el) ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[2,3-b] ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ CB2
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
CY1120101T1 (el) Παραγωγο πυριδονης και φαρμακο που το περιεχει